INTRODUCTION
ClinicalTrials.gov identifiers, NCT01252719 and NCT01252732, respectively) of a single intravenous (IV) dose of oritavancin compared to multiple-dose vancomycin administered IV for 7-10 days [1, 2] . Both clinical trials demonstrated that a single-dose of oritavancin was non-inferior to multiple-day vancomycin therapy. Since a full course of therapy is delivered in a single IV dose, oritavancin has the potential to shift the treatment of ABSSSI to the outpatient setting without compromising efficacy and without the need for laboratory monitoring (as is required with vancomycin) or an indwelling IV catheter [3] . This approach can affect how ABSSSI is managed, by reducing or in some cases eliminating costs and risks of hospitalization. 
METHODS
SOLO I and II were two identical, phase 3, multi-center, randomized, double-blind studies that compared the efficacy and safety of a single 1200 mg dose of IV oritavancin to vancomycin 1 g IV twice daily for 7-10 days in adults with ABSSSI [1, 2] . Patients randomized to oritavancin received placebo infusions twice daily to maintain treatment blinding. The SOLO I and SOLO II protocols were amended during the trials to allow patients to be managed in the outpatient setting at the discretion of the investigator. The SOLO trials study design was consistent with current regulatory guidelines for eligibility criteria, end points, assessment methods and non-inferiority margins.
Eligible patients were at least 18 years of age and had received a diagnosis of ABSSSI that was suspected or proven to be caused by a An algorithm based on the Eron classification was developed and applied to the modified intent-to-treat (mITT) pool of SOLO patients to classify each patient enrolled in the pooled dataset from the SOLO trials. The algorithm incorporated signs and symptoms of systemic illness in addition to concomitant medical conditions which have been implicated in poor therapeutic response (advanced age, chronic liver or renal disease, diabetes, obesity, chronic venous insufficiency) that were recorded in the case reports for each patient [6, 10] . Clinical variables included data collected in the SOLO trials, inclusion/ exclusion criteria, and input from clinical experts. The clinical criteria are described in Table 1 . Patients were classified into Class I-IV based on the presence of comorbidities and systemic symptoms of infection. Stratification criteria and assignment of patients to a modified Eron class were performed by expert consensus within a panel of seven advisors.
Patients categorized as Class IV (bacteremia or absolute neutrophil count less than 500 detected after enrollment) were excluded from this analysis as they were not considered appropriate for outpatient management.
Location of care in the outpatient or inpatient setting and all follow-up visits were documented in the case report form. and Drug Administration, hrs hours, IV intravenous, mITT modified intent-to-treat, PTE post-therapy evaluation (7-14 days after the end of therapy), Q every conducted using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Of the 1959 mITT patients in the SOLO studies, 520 (26.5%), 790 (40.3%), and 600 (30.6%) were categorized into Class I, II, and III, respectively ( 3 , or\4000 or[10% bandemia BMI body mass index, mITT modified intent-to-treat, MRSA methicillin-resistant Staphylococcus aureus, SD standard deviation, SIRS systemic inflammatory response syndrome Overall 40% (n = 767) of all patients in the SOLO trials were managed as outpatients. The percentages of patients treated entirely at an outpatient setting were 42.1%, 45.4%, and 31.5% in Class I, II, and III patients, respectively (Table 2) . Of the patients who were enrolled in the United States, 73% were managed in the outpatient setting and of those, 71% were Class II-III, which is similar to the overall study population. The combined efficacy for both drugs using the primary endpoint of clinical response at ECE for outpatients versus inpatients in Class I patients was 79% vs. 88.7%, Class II patients 82.7% vs. 84.7%, and 73% vs. 75.9% in Class III patients, respectively.
Within each Class (I-III), patients receiving oritavancin experienced similar clinical efficacy as those receiving vancomycin for the primary composite ECE outcome, lesion size reduction at ECE, and clinical cure at PTE. Treatment outcomes for oritavancin and vancomycin were also similar within each class when patients were analyzed by inpatient or outpatient management setting (Fig. 2) . Response rates at ECE for patients in Class III (75.0%) were lower than those observed with patients in Class I (84.6%, P\0.001) and Class II (83.8%, P\0.001).
However, at PTE the response rates did not differ between Class III (79.1%) and Class I (82.3%, P = 0.293) or Class II (81.1%, P = 0.542). mITT modified intent-to-treat, OPAT outpatient parenteral antibiotic therapy, ORI oritavancin, PTE post-therapy evaluation (7- One limitation to this analysis is that while the Eron/CREST treatment guidelines provide an approach to patient stratification, they have not been rigorously validated by clinical studies. The Eron classification has been criticized for being ambiguous with respect to the patient characteristics in the different severity classifications as well as being difficult to translate into real world treatment protocols [7, 8] . However, the Eron classification incorporates several important patient factors and was shown in a retrospective analysis of Premier database that Eron Classes I-IV correlated with increasing Charlson Comorbidity Index score, proportion of inpatients, in-hospital mortality rate, length of hospital stay, cost per patient and the use of MRSA-active antibiotics [11] .
CONCLUSIONS
The results demonstrate that single-dose oritavancin is an effective alternative to 7-10 days of IV vancomycin for the treatment of patients with ABSSSI within modified Eron Classes I-III. Management in the inpatient or outpatient setting was associated with comparable efficacy. Tools such as the Eron classification may be useful in the identification of patients with ABSSSI that could be managed in the outpatient setting, thereby avoiding hospitalization.
